fashion -WSS

fashion

author：knowledge 2025-09-06 04:37:31 - browse：4171

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Eating disorder hotline's move to chatbot carried cost for volunteers

knowledge

hotspot

WSS

Here's how to stay safe from wildfire smoke amid reduced air quality

The haunting brain science of long Covid

UnitedHealth wins $3.3 billion takeover of Amedisys

Why do we get seasonal allergies?

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

UHS says company favors patients whose insurance pays more

hotspot

fashion

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Wildfire smoke exposes gaps in outdoor worker protections

A new crop of companies is reshaping the health data economy

Peter Hotez and the public health issue of online harassment

Why do we get seasonal allergies?

Hepatitis C has a cure — but many Americans still lack access to it

New Alzheimer's drugs heat up race for early detection blood tests

Dobbs anniversary: the lost opportunity of abortion as health care

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

focus

The strange history of BMI, the body mass index

Supreme Court strikes down Biden student loan forgiveness program

Search called off for baby washed away in Pennsylvania flash flood

Synthetic human embryos? Researchers say term is overblown

Will the FTC rein in IQVIA's health data empire?

UHS says company favors patients whose insurance pays more

focus

knowledge

hotspot

leisure time